Reverse Cardiac Remodeling and ARNI Therapy
Cardiac remodeling is defined as a group of molecular, cellular, and interstitial changes that manifest clinically as changes in size, mass, geometry, and function of the heart after injury. The process results in a poor prognosis because of its association with ventricular dysfunction and malignant arrhythmias. Reverse remodeling has become a primary objective in HF treatment which is achieved with the help of guideline-directed medical and device therapies (GDMT). Combined angiotensin receptor/neprilysin inhibitor (ARNI) therapy has become a widely accepted component of GDMT. In this regard, Andrew Abboud and colleagues have published a review paper in the Current Heart Failure Reports under the title “Reverse Cardiac Remodeling and ARNI Therapy”. The summary of this review is given below:
To review the effect of GDMT, specially ARNI therapy on cardiac remodeling.
The review was conducted from the currently available evidence and scientific and medical knowledge.
Studies of ARNI therapy in HFrEF indicated a clear benefit in mortality and health status along with an impressive signal for early reverse cardiac remodeling with the use of sacubitril/valsartan. The treatment with sacubitril/valsartan has become a necessary component from GDMT for HF therapy.
Authors acknowledge future studies to understand the role of ARNI therapy in HFpEF.
Image Credit : Hand photo created by jcomp – www.freepik.com